Vol.23 No.2

Original Article

Pre-dinner administration increases the efficacy of proton pump inhibitors on refractory GERD symptoms in connective tissue disease patients

Authors

Arifumi Iwata1 , Kei Ikeda1 , Koichi Hirose1 , Hiroaki Takatori1 , Kentaro Takahashi1 , Yoshie Sanayama1 , Shigeru Tanaka1 , Akira Suto1 , Hiroshi Nakajima1

  • Department of Allergy and Clinical Immunology, Chiba University Hospital, 1-8-1 Inohana, Chiba, Chiba, 260-8670, Japan
Received:

13 January 2012

Accepted:

23 April 2012

Published online:

22 May 2012

Full Text

PDF (member's only)

Abstract

Background A significant proportion of patients with connective tissue disease (CTD) have gastric esophageal reflux disease (GERD) symptoms despite receiving proton pump inhibitors (PPIs). Although pre-meal administration of PPIs is recommended in Western countries, the benefit of this administration timing in Japanese CTD patients with refractory GERD symptoms has not been proven.
Objective To determine whether pre-dinner administration of PPIs is more efficacious for refractory GERD symptoms in Japanese CTD patients.
Methods CTD patients receiving oral PPIs were instructed to take PPIs 1 h before dinner. Gastrointestinal symptoms were evaluated with frequency scale for the symptoms of GERD (FSSG) and gastrointestinal symptom rating scale (GSRS) before and after the intervention.
Results Pre-dinner administration of PPIs significantly improved FSSG total score, from a median of 8 to 6.5 (P = 0.005). Pre-dinner administration was more effective in patients with overt GERD symptoms (from median 18 to 10, P<0.001) than in those with mild GERD symptoms (from median 2 to 2, P = 0.201). In addition to reflux syndrome, pre-dinner administration of PPIs significantly decreased abdominal pain syndrome and constipation syndrome of GSRS.
Conclusion Pre-dinner administration of PPIs may increase their efficacy in Japanese CTD patients with GERD, especially those with overt symptoms.

Key words

Proton pump inhibitor - Gastric esophageal reflux disease - Connective tissue disease - Administration time